Sei Investments Co. Boosts Stock Holdings in Vericel Co. (NASDAQ:VCEL)

Sei Investments Co. grew its position in shares of Vericel Co. (NASDAQ:VCEL) by 8.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,274 shares of the biotechnology company’s stock after purchasing an additional 3,253 shares during the quarter. Sei Investments Co.’s holdings in Vericel were worth $2,220,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of VCEL. Dimensional Fund Advisors LP increased its holdings in shares of Vericel by 9.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 506,214 shares of the biotechnology company’s stock valued at $15,633,000 after purchasing an additional 44,061 shares in the last quarter. Texas Permanent School Fund purchased a new position in shares of Vericel during the 1st quarter valued at approximately $1,907,000. Victory Capital Management Inc. purchased a new position in shares of Vericel during the 1st quarter valued at approximately $12,573,000. Commonwealth Equity Services LLC acquired a new stake in Vericel in the 1st quarter valued at $621,000. Finally, Envestnet Asset Management Inc. acquired a new stake in Vericel in the 1st quarter valued at $524,000. 99.88% of the stock is owned by hedge funds and other institutional investors.

A number of research firms recently issued reports on VCEL. Zacks Investment Research raised shares of Vericel from a “sell” rating to a “hold” rating in a research note on Tuesday, August 10th. Oppenheimer reissued a “hold” rating on shares of Vericel in a research note on Wednesday, June 30th. Finally, SVB Leerink dropped their price target on shares of Vericel from $67.00 to $62.00 and set an “outperform” rating on the stock in a research note on Thursday, August 5th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $49.50.

In other news, COO Michael Halpin sold 20,000 shares of the business’s stock in a transaction dated Monday, July 12th. The shares were sold at an average price of $53.54, for a total transaction of $1,070,800.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Sean C. Flynn sold 2,800 shares of the business’s stock in a transaction dated Wednesday, July 21st. The shares were sold at an average price of $55.01, for a total transaction of $154,028.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,800 shares of company stock worth $1,736,628. Corporate insiders own 4.60% of the company’s stock.

Shares of VCEL opened at $49.55 on Friday. Vericel Co. has a 52-week low of $17.78 and a 52-week high of $68.94. The firm’s fifty day moving average is $52.20 and its two-hundred day moving average is $53.83. The stock has a market cap of $2.31 billion, a PE ratio of 275.29 and a beta of 2.08.

Vericel (NASDAQ:VCEL) last announced its earnings results on Tuesday, August 3rd. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). Vericel had a net margin of 5.78% and a return on equity of 6.49%. The company had revenue of $39.52 million for the quarter, compared to analysts’ expectations of $36.78 million. During the same quarter in the previous year, the company posted ($0.18) EPS. The firm’s quarterly revenue was up 97.5% on a year-over-year basis. On average, sell-side analysts predict that Vericel Co. will post 0.07 EPS for the current year.

About Vericel

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee.

Read More: Trading signals using Bollinger bands

Want to see what other hedge funds are holding VCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vericel Co. (NASDAQ:VCEL).

Institutional Ownership by Quarter for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.